IRVINE, Calif. and LIEGE, Belgium, May 20, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the results of the ConfirmMDx® for Prostate Cancer clinical utility study will be published in the journal American Health and Drug Benefits (2014;7(3):129-134: www.AHDBonline.com). The study demonstrated a 10-fold reduction in the repeat biopsy rate in the ConfirmMDx-negative patient cohort as compared to the reported rate of repeat biopsy under the current standard of care.
Help employers find you! Check out all the jobs and post your resume.
